About PepGen
PepGen (NASDAQ:PEPG) is a biotechnology firm focused on the development of transformative therapies for neuromuscular and neurologic diseases. With a robust pipeline of innovative treatments, the company is dedicated to addressing some of the most challenging medical conditions, including Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy. By leveraging its cutting-edge Enhanced Delivery Oligonucleotide (EDO) platform, PepGen aims to unlock new possibilities in genetic medicine, improving the lives of patients worldwide. The company's objectives center on advancing its clinical trials, expanding its research and development efforts, and fostering partnerships to accelerate the availability of groundbreaking therapies. PepGen's commitment to science and patient care drives its pursuit of excellence and innovation in the biotech landscape.
Snapshot
Operations
Products and/or services of PepGen
- Development of enhanced delivery oligonucleotides (EDOs) for addressing neuromuscular and other severe diseases by improving cellular uptake and distribution.
- Progress on EDO51, aimed at treating Duchenne Muscular Dystrophy, focusing on skipping exon 51 to produce functional dystrophin.
- Advancement of EDO-NM for treating Myotonic Dystrophy Type 1, utilizing EDO technology to target the underlying genetic cause.
- Research on EDO-AOC, targeting Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), focusing on delivering antisense oligonucleotides to affected areas.
- Exploration of EDO-based therapies for cardiac diseases, aiming at genetic targets linked to heart function and diseases.
- Initiation of early-stage research projects targeting other genetic disorders using EDO technology, exploring broader therapeutic applications.
PepGen executive team
- Dr. James G. McArthur Ph.D.President, CEO, Treasurer, Secretary & Director
- Mr. Noel P. Donnelly M.B.A.Chief Financial Officer
- Dr. Paul D. Streck M.B.A., M.D.Executive VP and Head of Research & Development
- Dr. Michael Gait Ph.D.Founder & Scientific Advisory Board Member
- Dr. Kasra Kasraian Ph.D.Chief Technology Officer
- Ms. Emiko BryantSenior Vice President of HR & Administration
- Mr. Joseph D. Vittiglio Esq., J.D.Chief Business & Legal Officer
- Dr. Hayley Parker Ph.D.Senior Vice President of Global Regulatory Affairs
- Dr. Afsaneh Mohebbi Ph.D.Senior VP of Portfolio and Program Management